ERBB2 and breast carcinoma: Upon injection into the body, these probes bind to the membrane receptors, enabling the visualization of Her2‐positive breast cancer lesions through immunoPET imaging.[36, 37] This research is currently under the clinical trial stage (NCT05955833).[38] A key feature of this method is that the antibody remains extracellular, binding exclusively to membrane surface receptors.